Cogent Biosciences (COGT) Deferred Taxes (2017 - 2018)
Cogent Biosciences' (COGT) quarterly Deferred Taxes came in at -$17000.0 in Q4 2018, down 240.0% year-on-year from $12142.9 in Q4 2017, and little changed on a QoQ basis from -$17000.0 in Q3 2018.
Cogent Biosciences (COGT) Deferred Taxes (2017 - 2018) Analysis & Trends
Cogent Biosciences (COGT) has 2 years of Deferred Taxes data on file, last reported at -$17000.0 in Q4 2018.
- On a quarterly basis, Deferred Taxes fell 240.0% year-over-year to -$17000.0 in Q4 2018; TTM through Dec 2018 was -$52000.0, a 2500.0% decrease from a year earlier, with the FY2018 full-year figure at -$52000.0, down 2500.0% from the prior year.
- Deferred Taxes for Q4 2018 stood at -$17000.0, roughly flat from -$17000.0 in the prior quarter.
- Over the last five years, Deferred Taxes for COGT reached as high as $8000.0 in Q1 2017 and fell as low as -$17000.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -859,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Cogent Biosciences | 6.45 Bn | 6.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -17,000.00 |
| Sep 30, 2018 | -17,000.00 |
| Jun 30, 2018 | -14,000.00 |
| Mar 31, 2018 | -4,000.00 |
| Dec 31, 2017 | -5,000.00 |
| Sep 30, 2017 | -4,000.00 |
| Jun 30, 2017 | -1,000.00 |
| Mar 31, 2017 | 8,000.00 |